ClinicalTrials.gg
CompletedNCT00362206Updated Jul 8, 2009

Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin

A Phase 3 interventional study of Fenofibrate/Simvastatin and Fenofibrate/Simvastatin in Hyperlipidemia, sponsored by Solvay Pharmaceuticals. Completed at 41 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-07-08.

Sponsored by Solvay Pharmaceuticals (part of Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
423
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing fenofibrate in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Fenofibrate · Hyperlipidemias.

Enrollment
4th of 14
423 · median 178
Started
2006
with 1 other
Phase 3
7 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
4 of 14
Solvay Pharmaceuticals

Among the 14 studies testing fenofibrate in Hyperlipidemias, this one is the 4th largest by enrollment, is one of 2 that started in 2006, is one of 7 in phase 3, and was the 7th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 14 studies testing fenofibrate in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About fenofibrate

Fenofibrate: first FDA approval 1993 (TRICOR (MICRONIZED)), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing fenofibrate in Hyperlipidemias as a file.
02

Study summary

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia.The overall objective of the study is to compare the efficacy and safety of combining fenofibrate and simvastatin versus pravastatin monotherapy in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

Keywords

  • Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin versus pravastatin
  • Hyperlipidemia Combined
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mixed dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Known to fenofibrates or simvastatin or pravastatin
  • Pregnant or lactating women
  • to fenofibrate or simvastatin or pravastatin
  • Unstable or severe cardiac disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
423 participants (actual)

Study arms

  • Experimental
    1

    Drug: Fenofibrate/Simvastatin

  • Experimental
    2

    Drug: Fenofibrate/Simvastatin

  • Active comparator
    3

    Drug: Pravastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 12 weeks of treatment in Triglycerides

    Time frame: 12 weeks

  2. Percent change from baseline to 12 weeks of treatment in HDL-C

    Time frame: 12 weeks

  3. Percent change from baseline to 12 weeks of treatment in LDL-C

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change from baseline to 12 weeks of treatment in Triglycerides

    Time frame: 24 weeks

  2. Percent change from baseline to 12 weeks of treatment in HDL-C

    Time frame: 24 weeks

  3. Percent change from baseline to 12 weeks of treatment in LDL-C

    Time frame: 24 weeks

07

Study locations

41 sites
  • Site 40
    Athens, Greece
  • Site 39
    Ioannina, Greece
  • Site 41
    Thessaloniki, Greece
  • Site 37
    Beer Yaakov, Israel
  • Site 19
    Haifa, Israel
  • Site 22
    Holon, Israel
  • Site 18
    Jerusalem, Israel
  • Site 38
    Kfar Saba, Israel
  • Site 17
    Ramat Gan, Israel
  • Site 21
    Ramat Gan, Israel
  • Site 20
    Rechovot, Israel
  • Site 24
    Safed, Israel
  • Site 23
    Tel-Aviv, Israel
  • Site 5
    Arad, Romania
  • Site 7
    Bacau, Romania
  • Site 1
    Bucuresti, Romania
  • Site 6
    Cluj-Napoca, Romania
  • Site 4
    Oradea, Romania
  • Site 3
    Ploiesti, Romania
  • Site 2
    Targu Mures, Romania
  • Site 27
    Barnaul, Russian Federation
  • Site 31
    Kemerovo, Russian Federation
  • Site 32
    Krasnoyarsk, Russian Federation
  • Site 25
    Moscow, Russian Federation
  • Site 28
    Novosibirsk, Russian Federation
  • Site 26
    Smolensk, Russian Federation
  • Site 29
    St. Petersburg, Russian Federation
  • Site 30
    Voronezh, Russian Federation
  • Site 10
    Alberton, South Africa
  • Site 9
    Bloemfontein, South Africa
  • Site 14
    Cape Town, South Africa
  • Site 35
    Durban, South Africa
  • Site 33
    Hillcrest, South Africa
  • Site 34
    Kempton Park, South Africa
  • Site 16
    Komatipoort, South Africa
  • Site 13
    Krugersdorp, South Africa
  • Site 11
    Parow, South Africa
  • Site 12
    Port Elizabeth, South Africa
  • Site 8
    Pretoria, South Africa
  • Site 36
    Umkomaas, South Africa
  • Site 15
    Worcester, South Africa
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2006
First posted
Aug 9, 2006
Start
Sep 2006
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Last update
Jul 8, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00362206
First posted
Aug 9, 2006
Start date
Sep 2006
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Jul 8, 2009

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fenofibrate · Simvastatin

Start the discussion